Performance measures in million hearts: 2 partners' perspective

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):587-8. doi: 10.1161/CIRCOUTCOMES.112.967018.
No abstract available

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Aspirin / therapeutic use
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Endpoint Determination
  • Evidence-Based Medicine
  • Health Policy
  • Health Promotion
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Incidence
  • National Health Programs* / legislation & jurisprudence
  • Platelet Aggregation Inhibitors / therapeutic use
  • Preventive Health Services* / legislation & jurisprudence
  • Prognosis
  • Program Development
  • Public Health* / legislation & jurisprudence
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior
  • Smoking Cessation
  • United States
  • Weight Loss

Substances

  • Antihypertensive Agents
  • Hypolipidemic Agents
  • Platelet Aggregation Inhibitors
  • Aspirin